Enliven Therapeutics (ELVN) Shares Outstanding (2019 - 2026)

Enliven Therapeutics has reported Shares Outstanding (Entity) for 8 years, with the latest figure at $60.9 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 24.17% year-over-year to $60.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.9 million (up 24.17% YoY) and the FY2025 annual result came in at $59.4 million, up 21.46% from the prior year.
• Shares Outstanding (Entity) advanced to $60.9 million in Q1 2026 per ELVN's latest filing, from $59.4 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $60.9 million in Q1 2026 and troughed at $6.6 million in Q1 2022.
• A 5-year average of $38.0 million and a median of $46.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) increased 0.04% in 2022, then surged 528.32% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $6.6 million in 2022, then soared by 528.32% to $41.3 million in 2023, then gained by 18.51% to $48.9 million in 2024, then advanced by 21.46% to $59.4 million in 2025, then climbed by 2.44% to $60.9 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $60.9 million, $59.4 million, and $59.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.